BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 15645408)

  • 1. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis.
    Patel D; Terrault NA; Yao FY; Bass NM; Ladabaum U
    Clin Gastroenterol Hepatol; 2005 Jan; 3(1):75-84. PubMed ID: 15645408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
    Thompson Coon J; Rogers G; Hewson P; Wright D; Anderson R; Cramp M; Jackson S; Ryder S; Price A; Stein K
    Health Technol Assess; 2007 Sep; 11(34):1-206. PubMed ID: 17767898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances.
    Nouso K; Tanaka H; Uematsu S; Shiraga K; Okamoto R; Onishi H; Nakamura S; Kobayashi Y; Araki Y; Aoki N; Shiratori Y
    J Gastroenterol Hepatol; 2008 Mar; 23(3):437-44. PubMed ID: 17683496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms.
    Parikh ND; Singal AG; Hutton DW; Tapper EB
    Am J Gastroenterol; 2020 Oct; 115(10):1642-1649. PubMed ID: 32530829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis.
    Arguedas MR; Chen VK; Eloubeidi MA; Fallon MB
    Am J Gastroenterol; 2003 Mar; 98(3):679-90. PubMed ID: 12650806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.
    Farhang Zangneh H; Wong WWL; Sander B; Bell CM; Mumtaz K; Kowgier M; van der Meer AJ; Cleary SP; Janssen HLA; Chan KKW; Feld JJ
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1840-1849.e16. PubMed ID: 30580095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria.
    Lim KC; Wang VW; Siddiqui FJ; Shi L; Chan ES; Oh HC; Tan SB; Chow PK
    Hepatology; 2015 Jan; 61(1):227-37. PubMed ID: 24638991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Setting ambitious targets for surveillance and treatment rates among patients with hepatitis C related cirrhosis impacts the cost-effectiveness of hepatocellular cancer surveillance and substantially increases life expectancy: A modeling study.
    Uyei J; Taddei TH; Kaplan DE; Chapko M; Stevens ER; Braithwaite RS
    PLoS One; 2019; 14(8):e0221614. PubMed ID: 31449554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic Resonance Imaging Is Cost-Effective for Hepatocellular Carcinoma Surveillance in High-Risk Patients With Cirrhosis.
    Kim HL; An J; Park JA; Park SH; Lim YS; Lee EK
    Hepatology; 2019 Apr; 69(4):1599-1613. PubMed ID: 30365164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis.
    Sarasin FP; Giostra E; Hadengue A
    Am J Med; 1996 Oct; 101(4):422-34. PubMed ID: 8873514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct costs of care for hepatocellular carcinoma in patients with hepatitis C cirrhosis.
    Tapper EB; Catana AM; Sethi N; Mansuri D; Sethi S; Vong A; Afdhal NH
    Cancer; 2016 Mar; 122(6):852-8. PubMed ID: 26716758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.
    Bolondi L; Sofia S; Siringo S; Gaiani S; Casali A; Zironi G; Piscaglia F; Gramantieri L; Zanetti M; Sherman M
    Gut; 2001 Feb; 48(2):251-9. PubMed ID: 11156649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation and budget impact analysis of the surveillance program for hepatocellular carcinoma in Thai chronic hepatitis B patients.
    Sangmala P; Chaikledkaew U; Tanwandee T; Pongchareonsuk P
    Asian Pac J Cancer Prev; 2014; 15(20):8993-9004. PubMed ID: 25374242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C and hepatocellular carcinoma.
    Yao F; Terrault N
    Curr Treat Options Oncol; 2001 Dec; 2(6):473-83. PubMed ID: 12057093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians.
    Likhitsup A; Parikh ND
    Pharmacoeconomics; 2020 Jan; 38(1):5-24. PubMed ID: 31573053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco-regional therapy for hepatocellular carcinoma within Milan criteria?
    Landman MP; Feurer ID; Pinson CW; Moore DE
    HPB (Oxford); 2011 Nov; 13(11):783-91. PubMed ID: 21999591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis.
    Andersson KL; Salomon JA; Goldie SJ; Chung RT
    Clin Gastroenterol Hepatol; 2008 Dec; 6(12):1418-24. PubMed ID: 18848905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
    Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
    Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
    J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis.
    Njei B; McCarty TR; Fortune BE; Lim JK
    Aliment Pharmacol Ther; 2016 Nov; 44(10):1090-1101. PubMed ID: 27640785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.